CHMP recommends Numient (levodopa-carbidopa modified release) for Parkinsons disease- Impax
Impax Laboratories, Inc.announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending that Numient (IPX 066), a modified-release oral capsule formulation of levodopa-carbidopa, be granted approval for the symptomatic treatment of adult patients with Parkinson's disease.
Comment:The FDA has approved in January 2015, extended-release oral carbidopa-levodopa known in the US as Rytary, from Impax Laboratories, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and /or manganese intoxication.
Comment: Allergan has filed at FDA carbidopa and levodopa extended-release capsules which is a generic version of Impax Laboratories' Rytary.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins